Drug
Aro 033
Aro 033: highest development phase Phase 1, developed by Arrowhead Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Arrowhead Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ARO-033 NCT07662096 | Phase 1 | Age-related Macular Degeneration |
Latest
No recent events.
Follow Aro 033 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.